Core Viewpoint - Yifan Pharmaceutical's innovative drug Yilishu has achieved commercial sales in five countries, contributing to significant revenue growth in the company's innovative drug segment, leading to a nearly 20% increase in net profit for the first half of the year [1][2]. Financial Performance - In H1, Yifan Pharmaceutical reported revenue of 2.635 billion yuan, a year-on-year increase of 0.11%, and a net profit of 304 million yuan, up 19.91%. In Q2 alone, the net profit reached 150 million yuan, reflecting a 40.48% year-on-year growth [1]. - The company's proprietary (including imported) drug sales revenue grew by 7.22%, while innovative drug sales surged by 169.57%, increasing the proportion of high-margin business [1]. Product Sales Breakdown - Within the domestic pharmaceutical business, 23 proprietary (including imported) products achieved sales exceeding 10 million yuan, totaling 1.657 billion yuan, a 10.41% increase year-on-year, accounting for 93.67% of domestic proprietary drug sales [2]. - The overseas pharmaceutical segment generated revenue of 332 million yuan, a 6.46% increase compared to the previous year [2]. Innovative Drug Highlights - Yilishu's cumulative shipments exceeded 220,000 units in H1, marking a substantial year-on-year growth of 96.02%. The drug was priced at $4,600 per unit in the U.S., approximately 14 times the domestic price [2]. - The company has established commercial partnerships in over 40 countries, with Yilishu approved for sale in 34 countries or regions and commercial sales initiated in five [2][3]. Strategic Partnerships and Collaborations - Acrotech, Yifan Pharmaceutical's partner in the U.S., has increased its purchase and sales targets for Yilishu, issuing binding purchase orders for over 40,000 units for 2025 [3]. - The company has formed a global business development center and signed agreements for the sale of various products in regions including Colombia, Central America, and Mexico [3].